Ionis Pharmaceuticals Inc. (Nasdaq: IONS) partner GlaxoSmithKline (NYSE:
GSK) will not initiate a Phase 3 outcome study of IONIS-TTR. Shares of
Ionis plummeted $13.91 to $21.35 while GlaxoSmithKline stock edged up 3
cents to $43.15.
No Phase 3 study for Ionis and GSK
May 26, 2016 at 13:46 PM EDT